Arrowhead Pharma (ARWR)

Apr 15, 2025, 4:00 PM EDT - 7 days ago

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Apr 4, 2025, 4:30 PM EDT - 18 days ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Mar 21, 2025, 5:56 PM EDT - 4 weeks ago

Arrowhead Pharmaceuticals Is Finally Arriving

Mar 10, 2025, 7:30 AM EDT - 6 weeks ago

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Mar 6, 2025, 8:45 AM EST - 6 weeks ago

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Feb 28, 2025, 9:00 AM EST - 7 weeks ago

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Feb 25, 2025, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Feb 19, 2025, 11:53 AM EST - 2 months ago

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Feb 18, 2025, 10:20 AM EST - 2 months ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

AUB CRK CYTK EXE KRYS MARA MP

Feb 10, 2025, 9:35 PM EST - 2 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript

Feb 10, 2025, 4:01 PM EST - 2 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

Feb 10, 2025, 8:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

SRPT

Jan 22, 2025, 5:54 PM EST - 3 months ago

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

B GWRE

Jan 22, 2025, 4:00 PM EST - 3 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Jan 17, 2025, 4:30 PM EST - 3 months ago

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Dec 23, 2024, 7:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Dec 11, 2024, 7:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Dec 3, 2024, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Dec 2, 2024, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Nov 26, 2024, 11:08 PM EST - 5 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript

Nov 26, 2024, 4:00 PM EST - 5 months ago

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

Nov 26, 2024, 7:00 AM EST - 5 months ago

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

SRPT

Nov 18, 2024, 7:31 AM EST - 5 months ago

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Nov 18, 2024, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

Nov 5, 2024, 7:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results

Nov 4, 2024, 7:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences

Nov 1, 2024, 7:30 AM EDT - 6 months ago

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome

Sep 23, 2024, 7:30 AM EDT - 7 months ago

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Sep 10, 2024, 7:30 AM EDT - 8 months ago

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

Sep 3, 2024, 11:01 AM EDT - 8 months ago

Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug

Sep 2, 2024, 6:36 AM EDT - 8 months ago

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Aug 21, 2024, 7:30 AM EDT - 8 months ago

Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Aug 14, 2024, 6:59 PM EDT - 8 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference (Transcript)

Aug 14, 2024, 1:30 PM EDT - 9 months ago

Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies

Aug 8, 2024, 4:01 PM EDT - 9 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results

Aug 8, 2024, 4:00 PM EDT - 9 months ago

Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street

Jul 26, 2024, 12:12 PM EDT - 9 months ago

Arrowhead Pharmaceutical: Driving To Commercialization

Jul 24, 2024, 7:30 AM EDT - 9 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results

Jun 25, 2024, 2:01 PM EDT - 10 months ago

Canva Upskills 70 Million Educators and Students Globally with New Teacher Certification Course

AGR

Jun 25, 2024, 1:55 PM EDT - 10 months ago

Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial

Jun 24, 2024, 7:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE

Jun 24, 2024, 4:51 AM EDT - 10 months ago

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

MRK NTLA VRNA XFOR

Jun 3, 2024, 7:30 AM EDT - 11 months ago

Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome

May 31, 2024, 7:30 AM EDT - 11 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences

May 29, 2024, 5:30 AM EDT - 11 months ago

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia

May 28, 2024, 6:04 AM EDT - 11 months ago

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia

May 20, 2024, 6:00 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

May 17, 2024, 10:44 AM EDT - 1 year ago

Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point

May 9, 2024, 9:23 PM EDT - 1 year ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results